A Phase 1, Open-Label, Randomised, 3-Treatment, 3-Period, Single-Dose, Crossover Study in Healthy Subjects to Compare the Pharmacokinetic Properties of Modified Release (MR) Formulations of MIN-101 Followed by Food Effect Testing of a Selected Formulation

Trial Profile

A Phase 1, Open-Label, Randomised, 3-Treatment, 3-Period, Single-Dose, Crossover Study in Healthy Subjects to Compare the Pharmacokinetic Properties of Modified Release (MR) Formulations of MIN-101 Followed by Food Effect Testing of a Selected Formulation

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs MIN 101 (Primary)
  • Indications Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors Minerva Neurosciences
  • Most Recent Events

    • 22 Jun 2017 According to a Minerva Neurosciences media release, company announced successful completion of a bridging trial to select an improved, gastric-resistant (GR) formulation of MIN-101 for planned phase III study.
    • 22 Jun 2017 Status changed from recruiting to completed, according to a Minerva Neurosciences media release.
    • 03 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top